Cholinergic receptor nicotinic alpha 6 subunit (CHRNA6) (CHRNA6)

The Alpha-6 nicotinic acetylcholine receptor (nAChR alpha-6), encoded by the CHRNA6 gene, is a subunit of the pentameric ligand-gated ion channels that mediate fast cholinergic neurotransmission in the central nervous system [3, 7, 8]. It is uniquely localized in the brain, primarily on dopaminergic neurons in the substantia nigra and ventral tegmental area, where it plays a critical role in regulating dopamine release [1, 3, 11]. This specific distribution makes it a high-interest therapeutic target for Parkinson's disease, where enhancing its activity may alleviate motor symptoms, and for nicotine addiction, where its modulation can influence the rewarding properties of tobacco [1, 5, 14]. Beyond the dopaminergic system, the alpha-6 subunit is found in the retina and locus coeruleus, suggesting involvement in visual signaling and arousal [3, 7, 10]. Pharmacological modulation of this receptor, using both selective agonists and antagonists like alpha-conotoxins, offers a pathway for developing precision treatments for neurodegenerative and psychiatric disorders [1, 11, 12]. Genetic variants in the CHRNA6 gene have also been linked to individual differences in smoking behavior and vulnerability to substance abuse [2, 5, 7]. Research continues to explore its potential in treating chronic pain and other conditions where cholinergic-dopaminergic crosstalk is critical [4, 11].

Other names

Alpha-6 nicotinic acetylcholine receptornAChR alpha 6Neuronal acetylcholine receptor subunit alpha-6Cholinergic receptor nicotinic alpha polypeptide 6CHNRA6

The alpha 6 nicotinic acetylcholine receptor acts as a ligand-gated ion channel that opens in response to the binding of acetylcholine or nicotine, allowing the influx of cations such as calcium and sodium [6, 8, 10]. This activation leads to the depolarization of dopaminergic neurons and the subsequent release of dopamine in the striatum and nucleus accumbens [3, 11, 15]. Drugs targeting this receptor work by either mimicking the endogenous ligand to enhance dopaminergic tone (agonists) or by blocking the receptor to reduce the reinforcing effects of addictive substances (antagonists) [1, 5, 12].